Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Get Involved

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Study Purpose

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).

- Must be treatment naïve or have had treatment no less than 6 months prior to enrollment.

- 18 years or older.

- Must be able to take pills.

- ECOG performance status of 0-3.

- Ability to understand and willingness to sign a written informed consent.

- Members of all racial and ethnic groups are eligible for this study.

Exclusion Criteria:

- History of hypersensitivity reactions attributed to beta-glucan.

- Patients receiving continuous or other ongoing immunosuppressive therapy.

- Uncontrolled intercurrent illness including, but not limited to, autoimmune diseases, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Any patients who have serious autoimmune toxicity during the study period, or those who have disease recurrence during the 6-week study period should be excluded and analyzed separately.

- Patients with mucosal melanoma.

- Patients with concurrent malignancy or recent history thereof

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT04513028
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Kelly McMasters
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Kelly M McMasters, MD
Principal Investigator Affiliation	University of Louisville
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Melanoma Stage III, Melanoma Stage IV

Additional Details

This is a clinical pilot study using oral beta-glucan on patients with advanced stage III-IV melanoma without evidence of disease receiving adjuvant Pembrolizumab. The aim is to see whether beta-glucan treatment in combination with Pembrolizumab may provide augmented immunologic phenotypes such as decreased peripheral MDSCs, enhanced T effector cell function, or enhanced cytokine production in the peripheral blood or plasm of enrolled subjects. Secondary outcome measures will include clinical endpoints such as recurrence, progression free survival and overall survival.

Arms & Interventions

Arms

Experimental: Treatment

All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan. Pembrolizumab: 200 mg/100mL IV in three week intervals Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days

Interventions

Dietary Supplement: - Beta-Glucan

500mg (1 capsule) by mouth twice a day for 21 days.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Louisville, Louisville 4299276, Kentucky 6254925

Status

Recruiting

Address

University of Louisville

Louisville 4299276, Kentucky 6254925, 40202

Site Contact

Matthew Woeste, MD

[email protected]

502-852-0325